Clinical Trials Browser

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroendocrine Tumors

NCT07488923 2026-04-29

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

Phase 1 Not yet recruiting

110 enrolled

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05142189 2026-04-14

LuCa-MERIT-1

Phase 1 Recruiting

320 enrolled

EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT07165132 2026-04-13

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Phase 1 Recruiting

104 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT05680922 2026-03-24

DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Phase 1 Active not recruiting

41 enrolled

EndocrineNETThoracic

Small Cell Lung Cancer Extensive Stage

NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Phase 1 Terminated

40 enrolled

CNSEndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

NCT06910657 2026-03-02

IDOV-Immune for Advanced Solid Tumors

Phase 1 Recruiting

78 enrolled

BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adrenal Gland Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Vaccinia, Colorectal Neoplasms

NCT03833700 2026-02-27

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Phase 1 Active not recruiting

70 enrolled

EndocrineGastrointestinalNETSarcoma

Gastro-enteropancreatic neuroendocrine tumor, Digestive System Neoplasms, Carcinoma, Hepatocellular, Colorectal Neoplasms, Desmoid Tumors, Adrenocortical Carcinoma

NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Phase 1 Recruiting

27 enrolled

EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT03746431 2026-01-07

A Phase 1 Study of [225Ac]-FPI-1434 Injection

Phase 1 Terminated

78 enrolled

BreastDermatologicEndocrineGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Adrenocortical Carcinoma, Triple Negative Breast Neoplasms

NCT07287748 2025-12-31

A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer

Phase 1 Recruiting

38 enrolled

EndocrineHead & Neck

DTC - Differentiated Thyroid Cancer

NCT07252661 2025-11-28

Study of ACC-1898 in Adult Participants With Advanced Solid Tumors

Phase 1 Not yet recruiting

40 enrolled

DermatologicEndocrineGastrointestinalGenitourinaryHead & Neck

Thyroid cancer, medullary, Carcinoma, Renal Cell, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis

NCT05364944 2025-11-17

OXTEND-01

Phase 1 Terminated

19 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Acromegaly

NCT07181720 2025-10-02

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

Phase 1 Recruiting

90 enrolled

EndocrineGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thymoma, Thyroid Carcinoma, Anaplastic

NCT06805825 2025-09-23

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

Phase 1 Recruiting

67 enrolled

DermatologicEndocrineGastrointestinalGenitourinaryNETSarcomaThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Carcinoma, Adenoid Cystic, Piebaldism, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT06505824 2025-09-18

A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors

Phase 1 Recruiting

22 enrolled

EndocrineNETThoracic

Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT06577987 2025-09-15

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

Phase 1 Recruiting

220 enrolled

BreastEndocrineNETThoracic

Breast Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Triple Negative Breast Neoplasms

Clinical Trials

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

KinLET

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

LuCa-MERIT-1

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

IDOV-Immune for Advanced Solid Tumors

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Sapu003 in Advanced mTOR-sensitive Solid Tumors

A Phase 1 Study of [225Ac]-FPI-1434 Injection

A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer

Study of ACC-1898 in Adult Participants With Advanced Solid Tumors

OXTEND-01

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

DeLLpro-300

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET

HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Study of rSIFN-co for Patients With Advanced Solid Tumors

Phase 1 Study of 68Ga-R8760

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women

177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body

A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants

A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants

A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver

DUET-2

A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

DUET-1

LTW